Generate Biomedicines, Inc. IPO prospectus (424B4)
SEC 424B4, prospectus dated 26 February 2026, filed 27 February 2026. The cover carries the date February 26, 2026; the EDGAR filing list gives 2026-02-27.
- Issued by
- No issuing record yet. A missing record is a gap in coverage.
- Authors credited
- No authorship claim recorded yet. The source record lists Generate Biomedicines, Inc. (filed with the US SEC).
- Dates
- No date claim recorded yet. The source record gives the publication date as 2026-02-26.
- Exact source
- Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock Generate Biomedicines, Inc. (filed with the US SEC) · published 2026-02-26 · Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30.
Appears in
No collection holds a record about this document yet.
Versions
No other versions of this document are recorded. The evidence applies to the source version listed above. Other versions, such as a preprint, working paper or journal publication, are not identified or substituted.
Documentary relations
Each relation is listed separately. Citing, crediting and reporting the use of a method are different acts, and none of them shows agreement or influence by itself.
Not recorded for this document: cites · cited by · explicitly credits · reports using a method from · method reported as used by · applies parts of · parts applied by · discusses · reports evaluation of. A missing record does not show that the relation does not exist.
What the document states
A limited selection of what this document states, each with its passage. It describes the text, not whether anyone acted on it.
- Statementcollaborations as stated: Amgen (December 2021; $50.0 million upfront received January 2022) and Novartis (September 2024; $50.0 million upfront received October 2024)“In December 2021, we entered into a collaboration and license agreement with Amgen, as amended (as amended from time to time, the “Amgen Collaboration Agreement”), and, in connection therewith, we received a non-refundable upfront payment of $50.0 million in January 2022”Risk factors, paragraph beginning "To date, we have financed our operations" (prospectus p. 19)Inspect claim & evidence ↗
- Statementplatform description: generative and predictive models, including diffusion-based models such as Chroma“The Generate Platform integrates generative and predictive models that learn design principles from proprietary data—e.g., diffusion-based models (such as our Chroma model) and graph neural networks, among other architectures”Prospectus summary, "The Generate Platform"Inspect claim & evidence ↗
- Statementcompany statement: GB-0895 in two Phase 3 trials for severe asthma; first patient dosed 26 January 2026“We are currently enrolling patients in two parallel global Phase 3 clinical trials for GB-0895 initiated in December 2025 (SOLAIRIA-1 and SOLAIRIA-2) for severe asthma, with full enrollment expected by the first half of 2028.”Prospectus summary, "Overview"Inspect claim & evidence ↗
- Statementframing statement: "Biology is an information science."“Biology is an information science. DNA encodes biological function through the way its sequence determines the structure and activity of the molecules it produces, which, in principle, makes biology programmable.”Prospectus summary, "Overview"Inspect claim & evidence ↗
- Statementinitial public offering: 25,000,000 shares at $16.00; Nasdaq symbol GENB“This is the initial public offering of shares of common stock of Generate Biomedicines, Inc. We are offering 25,000,000 shares of our common stock.”Prospectus coverInspect claim & evidence ↗